{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:34Z","timestamp":1792782694705,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fundamental Fund from Thailand Science Research and Innovation","id":[{"id":"https:\/\/ror.org\/000025p04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Senior Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04952-3","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:07:30Z","timestamp":1789632450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients"],"prefix":"10.1007","volume":"96","author":[{"given":"Supavich","family":"Tannumsaeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanarat","family":"Anurathapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpatsorn","family":"Sermcheep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattara","family":"Kanjanakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayamon","family":"Takpradit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleebsabai","family":"Sanpakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimjai","family":"Niparuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakrit","family":"Piyajaroenkij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adisak","family":"Tantiworawit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korakot","family":"Atjanasuppat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piamsiri","family":"Sawaisorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarinthip","family":"Preedagasamzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunyada","family":"Jittorntrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Prasongtanakij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samart","family":"Pakakasama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"4952_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/blood-2013-10-532598","volume":"123","author":"V Conter","year":"2014","unstructured":"Conter V, Valsecchi MG, Parasole R et al (2014) Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood 123:1470\u20131478","journal-title":"Blood"},{"key":"4952_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3109\/10428194.2011.631156","volume":"53","author":"P Surapolchai","year":"2012","unstructured":"Surapolchai P, Pakakasama S, Sirachainan N et al (2012) Comparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience. Leuk Lymphoma 53:891","journal-title":"Leuk Lymphoma"},{"key":"4952_CR3","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41409-021-01267-0","volume":"56","author":"A Sharma","year":"2021","unstructured":"Sharma A, Li Y, Huang S, Talleur AC et al (2021) Outcomes of pediatrics who relapse after first HCT for acute leukemia or MDS. Bone Marrow Transplant 56:1866\u20131875","journal-title":"Bone Marrow Transplant"},{"key":"4952_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449\u2013459","journal-title":"N Engl J Med"},{"key":"4952_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jcyt.2016.07.003","volume":"18","author":"MB Geyer","year":"2016","unstructured":"Geyer MB, Brentjens RJ (2016) Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy 18:1393\u20131409","journal-title":"Cytotherapy"},{"key":"4952_CR6","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/trf.14569","volume":"58","author":"F Ceppi","year":"2018","unstructured":"Ceppi F, Rivers J, Annesley C et al (2018) Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion 58:1414\u20131420","journal-title":"Transfusion"},{"key":"4952_CR7","doi-asserted-by":"publisher","first-page":"e005701","DOI":"10.1136\/jitc-2022-005701","volume":"11","author":"F Song","year":"2023","unstructured":"Song F, Hu Y, Zhang Y et al (2023) Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J Immunother Cancer 11:e005701","journal-title":"J Immunother Cancer"},{"key":"4952_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li C, Du M et al (2023) Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J 13:61","journal-title":"Blood Cancer J"},{"key":"4952_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) Off-the-shelf allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19:185\u2013199","journal-title":"Nat Rev Drug Discov"},{"key":"4952_CR10","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang XQ, Zhang RL et al (2021) Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL allotransplant. Leukemia 35:1563\u20131570","journal-title":"Leukemia"},{"key":"4952_CR11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2023-179042","volume":"142","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, Becilli M, Rosignoli et al (2023) Allogeneic, donor-derived, second generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood 142:146\u2013157","journal-title":"Blood"},{"key":"4952_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"K Sanber","year":"2021","unstructured":"Sanber K, Sanavi B, Jain T (2021) Graft-versus host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol 195:660\u2013668","journal-title":"Br J Haematol"},{"key":"4952_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/ajco.13474","volume":"18","author":"S Prasongtanakij","year":"2022","unstructured":"Prasongtanakij S, Anurathapan U, Vanichapol T et al (2022) Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL. Asia Pac J Clin Oncol 18:44\u201351","journal-title":"Asia Pac J Clin Oncol"},{"key":"4952_CR14","doi-asserted-by":"publisher","first-page":"e0281735","DOI":"10.1371\/journal.pone.0281735","volume":"18","author":"P Sawaisorn","year":"2023","unstructured":"Sawaisorn P, Atjanasuppat K, Uaesoontrachoon K et al (2023) Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models. PLoS ONE 18:e0281735","journal-title":"PLoS ONE"},{"key":"4952_CR15","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","volume":"117","author":"E Coutan-Smith","year":"2011","unstructured":"Coutan-Smith E, Song G, Clark C et al (2011) New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117:6267\u20136276","journal-title":"Blood"},{"key":"4952_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl 25:625\u2013638","journal-title":"Biol Blood Marrow Transpl"},{"key":"4952_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","volume":"268","author":"EC Tallantyre","year":"2021","unstructured":"Tallantyre EC, Evans NA, Parry-Jones Jet at. (2021) Neurological Updates: Neurological Complications of CAR-T Therapy. J Neurol 268:1544\u20131554","journal-title":"J Neurol"},{"key":"4952_CR18","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S et al (2023) Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol 41:1664\u20131669","journal-title":"J Clin Oncol"},{"key":"4952_CR19","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K et al (2021) Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia 35:3383\u20133393","journal-title":"Leukemia"},{"key":"4952_CR20","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO et al (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:4129\u20134139","journal-title":"Blood"},{"key":"4952_CR21","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/ijms24065688","volume":"24","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager V, Bacher U, Seipel K et al (2023) CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma. Int J Mol Sci 24:5688","journal-title":"Int J Mol Sci"},{"key":"4952_CR22","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","volume":"5","author":"S Faude","year":"2021","unstructured":"Faude S, Wei J, Muralidharan K et al (2021) Absolute Lymphocyte Count Proliferation Kinetics after CAR T-Cell Infusion Impact Response and Relapse. Blood Adv 5:2128\u20132136","journal-title":"Blood Adv"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04952-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04952-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04952-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:07:31Z","timestamp":1789632451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04952-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04952-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9568776\/v1","asserted-by":"object"}]},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Clearance Committee on Human Rights Related to Research Involving Human Subjects, Faculty of Medicine Ramathibodi Hospital, Mahidol University (COA. MURA2023\/504). All patients and parents who participated in this study provided their consents.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"107"}}